### Edgar Filing: PRESSURE BIOSCIENCES INC - Form 4

PRESSURI Form 4 January 30,	E BIOSCIENCES 2014	INC								
FORM	ЛЛ							• • • • • •	PPROVA	L
-	UNITED	STATES		RITIES A	E COMMISSIO	N OMB Number:	3235-	0287		
Check t if no los subject Section Form 4	to <b>STATEN</b> 16.	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES						Estimated burden hou	Expires: Janual Estimated average burden hours per response	
Form 4 or Form 5 obligations may continue.response0.5See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.5										
(Print or Type	Responses)									
Pollack Kevin Symbol Issuer							f Reporting Person(s) to			
			PRESSURE BIOSCIENCES INC [PBIO]				(Check all applicable)			
(Last) (First) (Middle) 14 NORFOLK AVE.			3. Date of Earliest Transaction (Month/Day/Year) 01/30/2014			X_ Director 10% Owner Officer (give title Other (specify below) below)				
(Street) 4. If Amendment, Date Orig Filed(Month/Day/Year)					-	Applicable Line) _X_ Form filed by One Reporting Person				
SOUTH E	ASTON, MA 023	75					Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativ	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or d of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownersh (Instr. 4)	ıl
Reminder: Re	port on a separate line	for each cla	ass of sec				or indirectly.			
					Pers infor requ	ons who res mation cont ired to resp	spond to the colle tained in this forn ond unless the fo	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amou
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securi
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

number.

#### Edgar Filing: PRESSURE BIOSCIENCES INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)		Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
				Code V	V	(A) (D)	Date Exercisable	Expiration Date	Title	Am or Nur of S
Series K Convertible Preferred Stock	\$ 0.25	01/30/2014		Р		90	01/30/2014(1)	01/30/2015	Common Stock	90,
Series K Common Stock Purchase Warrant	\$ 0.3125	01/30/2014		Р		45,000	01/30/2014 <u>(3)</u>	01/30/2017	Common Stock	45,

# **Reporting Owners**

Reporting Owner Name / Addr	Relationships							
inporting of the round ( round	Director	10% Owner	Officer	Other				
Pollack Kevin 14 NORFOLK AVE. SOUTH EASTON, MA 023	X 75							
Signatures								
/s/ Kevin Pollack	01/30/2014							
**Signature of Reporting Person	Date							

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The terms of the Series K Convertible Preferred Stock contain a limitation on conversion which prevents the Reporting Person from converting shares of Series K Convertible Preferred Stock if, after giving effect to the conversion, the Reporting Person would beneficially own more than 4.99% of the outstanding shares of Common Stock. The Reporting Person may elect to increase this

(1) limitation to 9.99%, 14.99%, or 19.99% upon not less than 61 days prior written notice to the Company. Since the Reporting Person currently beneficially owns less than 4.99% of the outstanding shares of Common Stock, the conversion limitation that applies to the Reporting Person is the 4.99% limitation. The Reporting Person disclaims beneficial ownership of such securities except to the extent of the Reporting Person's pecuniary interest in such securities.

Pursuant to a certain Securities Purchase Agreement dated January 30, 2014, among the Company, the Reporting Person, and the other purchasers named therein, the Reporting Person purchased 90 "Units" at a purchase price of \$250 per Unit. Each Unit consisted of (i) one share of Series K Convertible Preferred Stock, convertible into 1,000 shares of the Company's Common Stock, and (ii) a warrant to

- purchase 500 shares of Common Stock, which warrant is exercisable until January 30, 2017
- (3) The Series K Common Stock Purchase Warrants contain a limitation on exercise which prevents the Reporting Person from exercising any Warrants if, after giving effect to the exercise, the Reporting Person would beneficially own more than 4.99% of the outstanding shares of Common Stock. The Reporting Person may elect to increase this limitation to 9.99%, 14.99%, or 19.99% upon not less than 61

(2)

#### Edgar Filing: PRESSURE BIOSCIENCES INC - Form 4

days prior written notice to the Company. Since the Reporting Person currently beneficially owns less than 4.99% of the outstanding shares of Common Stock, the exercise limitation that applies to the Reporting Person is the 4.99% limitation. The Reporting Person disclaims beneficial ownership of such securities except to the extent of the Reporting Person's pecuniary interest in such securities

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.